Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Motor function recovery in patients after ischemic stroke

https://doi.org/10.14412/2074-2711-2019-3S-89-94

Full Text:

Abstract

Secondary prevention of recurrent stroke and other cardiovascular diseases is of key importance for the management of a patient after ischemic stroke. Medications (antihypertensive, antiplatelet, or anticoagulant drugs and statins) are recommended for use; and a small proportion of patients should undergo surgical treatment (carotid endarterectomy); non-drug treatments (smoking cessation and alcohol abstinence, adherence to the Mediterranean diet, and increased physical activity) are of great importance. Movement disorders are seen in 80% of patients after a stroke and are the leading cause of disability. Therapeutic exercises aimed at training movements in the paretic limbs and at preventing the development of contractures are of utmost importance in post-stroke movement disorders. The use of citicoline to improve motor function recovery is discussed.

About the Author

Yu. A. Starchina
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine, 

11, Rossolimo St., Build. 1, Moscow 119021



References

1. Feigin V. Global, regional, and national disability-adjusted life years (Dalys) for 315 diseases and injuries and healthy life expectancy (Hale), 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1603-58. doi: 10.1016/S0140-6736(16)31460-X

2. Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 288 p. (In Russ.).

3. O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388:761-75. doi: 10.1016/S0140-6736(16)30506-2

4. Meijer R, Plotnik M, Zwaaftink EG, et al. Markedly impaired bilateral coordination of gait in post-stroke patients: Is this deficit distinct from asymmetry? A cohort study. J Neuroeng Rehabil. 2011;8:23. doi: 10.1186/1743-0003-8-23

5. Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374:525-33. doi: 10.1016/S0140-6736(09)61340-4

6. Bath PM, Scutt P, Blackburn DJ, et al. Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot 'Prevention of Decline in Cognition after Stroke Trial' (PODCAST) Randomised Controlled Trial. PLoS One. 2017;12(1):e0164608. doi: 10.1371/journal.pone.0164608

7. Rothwell PM, Howard SC, Spence JD, for the Carotide Endarterectomy Trialist`s Collaboration. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke. 2003;34:2583-92. doi: 10.1161/01.STR.0000094424.38761.56

8. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. doi: 10.1136/ bmj.324.7329.71

9. Diener HC, Weimar C. Update of secondary stroke prevention. Nephrol Dial Transplant. 2009;24:1718-24. doi: 10.1093/ndt/gfp068

10. CAPRIE Streering Commitee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-39. doi: 10.1016/S0140-6736(96)09457-3

11. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143: 1-13. doi: 10.1016/S0022-510X(96)00308-5

12. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2016;50(5):e1-e88.

13. Amarenco P, Labreuche J, Lavalle P, Touboul P-J. Statin in stroke prevention and carotid atherosclerosis: systematic review and meta-analysis. Stroke. 2004;35:2902-9. doi: 10.1161/01.STR.0000147965.52712.fa

14. Wannamethee SG, Shaper AG, Whincup PH, Walker M. Smoking cessation and the risk of stroke in middle-aged men. JAMA. 1995;274: 155-60. doi: 10.1001/jama.1995.03530020073035

15. Barnes JN. Exercise, cognitive function, and aging. Adv Physiol Educ. 2015;39(2):55-62. doi: 10.1152/advan.00101.2014

16. Canevelli M, Lucchini F, Quarata F, et al. Nutrition and Dementia: Evidence for Preventive Approaches? Nutrients. 2016;8(3): 144. doi: 10.3390/nu8030144

17. Baumgartner R, Oesch L, Sarikaya H. Obesity Paradox and Stroke. Praxis (Bern).2016; 105(14):835-41. doi: 10.1024/1661-8157/a002408

18. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery. A guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2016; 47:e98-e169. doi: 10.1161/STR.0000000000000098

19. Pollock A, Baer G, Campbell P, et al. Physical rehabilitation approaches for the recovery of function and mobility following stroke. Cochrane Database System Rev. 2014; (4):Art. No. CD001920. doi: 10.1002/14651858.CD001920.pub3

20. Damulin IV, Ekusheva EV. Poststroke neuroplasticity processes. Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(3):69- 74 (In Russ.). doi: 10.14412/2074-2711-2014-3-69-74

21. Mayo NE, Fellows LK, Scott SC, et al. A longitudinal view of apathy and its impact after stroke. Stroke. 2009;40:3299-307. doi: 10.1161/STROKEAHA.109.554410

22. Duncan F, Kutlubaev MA, Dennis MS, et al. Fatigue after stroke: a systematic review of associations with impaired physical fitness. Int J Stroke. 2012;7:157-62. doi: 10.1111/j.1747-4949.2011.00741.x

23. Gebruers N, Vanroy C, Truijen S, et al. Monitoring of physical activity after stroke: a systematic review of accelerometry-based measures. Arch Phys Med Rehabil. 2010;91: 288-97. doi: 10.1016/j.apmr.2009.10.025

24. Lincoln NB, Brinkmann N, Cunningham S, et al. Anxiety and depression after stroke: a 5 year follow-up. Disabil Rehabil. 2013;35:140-5. doi: 10.3109/09638288.2012.691939

25. Verbitskaya SV, Parfenov VA, Reshetnikov VA, et al. Post-stroke cognitive impairment (results of a 5-year follow-up). Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):37-42 (In Russ.). doi: 10.14412/2074-2711-2018-1-37-42

26. Gadidi V, Katz-Leurer M, Carmeli E, Bornstein NM. Long-term outcome poststroke: predictors of activity limitation and participation restriction. Arch Phys Med Rehabil. 2011; 92:1802-8. doi: 10.1016/j.apmr.2011.06.014

27. Kim JH, Sim WS, Won BH. Effectiveness of elastic band-type ankle-foot orthoses on postural control in poststroke elderly patients as determined using combined measurement of the stability index and body weight-bearing ratio. Clin Intervent Aging. 2015;10:1839-47. doi: 10.2147/CIA.S92888

28. Tiozzo E, Youbi M, Dave K, et al. Aerobic, resistance, and cognitive exercise training poststroke. Stroke. 2015;46:2012-6. doi: 10.1161/STROKEAHA.114.006649

29. Francisco GE, Boake C. Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. Arch Phys Med Rehabil. 2003;84:1194-9. doi: 10.1016/S0003-9993(03)00134-5

30. Shaw LC, Price CIM, van Wijck FMJ, et al. Botulinum Toxin for the Upper Limb After Stroke (BoTULS) Trial: Effect on Impairment, Activity Limitation, and Pain. Stroke. 2011; 42:1371-9. doi: 10.1161/STROKEAHA.110.582197

31. Ward AB, Wissel J, Borg J, et al. Functional goal achievement in post-stroke spasticity patients: the BOTOX® Economic Spasticity Trial (BEST). J Rehabil Med. 2014;46:504-13. doi: 10.2340/16501977-1817

32. Tolmacheva VA. Poststroke spasticity: An individualized approach to treatment. Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(4):71-6 (In Russ.). doi: 10.14412/2074-2711-2016-4-71-76.

33. Ding D, Lawson KD, Kolbe-Alexander TL, et al. The economic burden of physical inactivity: a global analysis of major non-communicable diseases. Lancet. 2016;388:1311-24. doi: 10.1016/S0140-6736(16)30383-X

34. Rist PM, Capistrant BD, Mayeda ER, et al. Physical activity, but not body mass index, predicts less disability before and after stroke. Neurology. 2017;88:1718-26. doi: 10.1212/WNL.0000000000003888

35. Reinholdsson M, Palstam A, Sunnerhagen KS. Prestroke physical activity could influence acute stroke severity (part of PAPSIGOT). Neurology. 2018 Oct 16;91(16): e1461-e1467. Epub 2018 Sep 19.

36. Wang Y, Li M, Dong F, et al. Physical exercise-induced protection on ischemic cardiovascular and cerebrovascular diseases. Int J Clin Exp Med. 2015;8:19859-66.

37. Middleton LE, Corbett D, Brooks D, et al. Physical activity in the prevention of ischemic stroke and improvement of outcomes: a narrative review. Neurosci Biobehav Rev. 2013;37: 133-7. doi: 10.1016/j.neubiorev.2012.11.011

38. Firth N, Barker RN, Hayward KS, et al. Safety and efficacy of recovery-promoting drugs for motor function after stroke: A systematic review of randomised controlled trials. J Rehabil Med. 2019 Feb 25 [Epub ahead of print].

39. Bustamante A, Giralt D, Garcia-Bonilla L, et al. Citicoline in pre-clinical animal models of stroke: a meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. J Neurochem. 2012;123(2):217-25. doi: 10.1111/j.1471-4159.2012.07891.x

40. Gutierrez-Fernandez M, Rodriguez-Frutos B, Fuentes B, et al. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int. 2012;60:310-7. doi: 10.1016/j.neuint.2011.12.015

41. Piradov MA, Sergeev DV, Krotenkova MV. Application of ceraxon in the acute period of hemispheric ischemic stroke: clinical and CT perfusion assessment. Annaly Klinicheskoi i Eksperimental'noi Nevrologii = Annals of Clinical and Experimental Neurology. 2012;(3):31-6 (In Russ.).

42. Secades JJ, Alvarez-Sabin J, Castillo J, et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis. 2016;25(8): 1984-96. doi: 10.1016/j.jstrokecerebrovasdis.2016.04.010

43. Kan T, et al. Drug effect evaluation of CDPcholine in after-effects of stroke by the multicenter double-blind method – Centering on a study by the hemiplegia function recovery 12-grade evaluation method. Jap J Clin Exper Med. 1976;53:3781.

44. Hazama T, Hasegawa T, Ueda S, Sakuma A. Evaluation of the effect of CDP-choline on poststroke hemiplegia employing a double-blind controlled trial. Assessed by a new rating scale for recovery in hemiplegia. Int J Neurosci. 1980; 11:211. doi: 10.3109/00207458009147587

45. Ueda S, Hasegawa T, Ando K, et al. Evaluation of the pharmacological effect of CDP-choline injection in post-stroke hemiplegia. Double-blind comparative study using the Hemiplegia Function Test (12-grade evaluation method). Strides Med. 1994;170:297-314.


For citation:


Starchina Y.A. Motor function recovery in patients after ischemic stroke. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3S):89-94. (In Russ.) https://doi.org/10.14412/2074-2711-2019-3S-89-94

Views: 104


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)